Nurses Can Help Mitigate Prostate Cancer Disparities

A Look Back at 2022 FDA Approvals in Oncology

Prostate Cancer Therapy Choice Does Not Significantly Impact Survival According to Long-Term Clinical Trial Follow-Up

Key Advances in Cancer Survivorship Toxicity Management

Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC

Atezolizumab Does Not Demonstrate Significant OS Benefit Over Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer

Nonpharmacologic Pain Intervention Reduces Opioid Use Following Minimally Invasive Gynecologic and Urologic Surgery

A Look Back at 2022 FDA Approvals in Oncology

Prostate Cancer Therapy Choice Does Not Significantly Impact Survival According to Long-Term Clinical Trial Follow-Up

Key Advances in Cancer Survivorship Toxicity Management

Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC

Atezolizumab Does Not Demonstrate Significant OS Benefit Over Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer

Nonpharmacologic Pain Intervention Reduces Opioid Use Following Minimally Invasive Gynecologic and Urologic Surgery

A Look Back at 2022 FDA Approvals in Oncology

Prostate Cancer Therapy Choice Does Not Significantly Impact Survival According to Long-Term Clinical Trial Follow-Up

Key Advances in Cancer Survivorship Toxicity Management

Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC

Atezolizumab Does Not Demonstrate Significant OS Benefit Over Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer

Nonpharmacologic Pain Intervention Reduces Opioid Use Following Minimally Invasive Gynecologic and Urologic Surgery

Related Content

A Look Back at 2022 FDA Approvals in Oncology

The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.

Prostate Cancer Therapy Choice Does Not Significantly Impact Survival According to Long-Term Clinical Trial Follow-Up

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Key Advances in Cancer Survivorship Toxicity Management

Patients with prostate cancer experienced prostate cancer-specific mortality at a low rate regardless of assigned treatment.

Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC

Podcast

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.

Atezolizumab Does Not Demonstrate Significant OS Benefit Over Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.